Suche klinische Studie
Weitere Suchoptionen
77 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
NIEDERLANDE
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors - UK
Institution: Information not provided - UK
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
BELGIEN
NAMUR
YVOIR
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - BE
Cliniques Universitaires UCL de Mont-Godinne
Department of Hematology
BELGIEN
OOST-VLAANDEREN
GENT
Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer - BE
Ghent University Hospital - UZ Gent
Department of Gastrointestinal Surgery
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
CHARLY: Eine Studie zum Stellenwert von Cyclophosphamid nach Thiotepa-Basierter Haplo-identer Stammzelltransplantation für refraktäre non-Hodgkin Lymphome
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Berlin
BERLIN
RADIANT-4: Eine randomisierte, doppelblinde, multizentrische Phase III-Studie zur Beurteilung der Wirksamkeit von Everolimus (RAD001) mit best-supportive care im Vergleich zu Placebo plus best-supportive care bei Patienten mit fortgeschrittenen neuroendokrinen Tumoren des Gastrointestinaltraktes und der Lunge
Charité - Universitätsmedizin Berlin (CVK)
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie (CVK)
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
ACT-1: Eine randomisierte Phase III-Studie zur Bewertung der Wirksamkeit von Chemoimmuntherapie mit dem monoklonalen Antikörper Campath-1H (Alemtuzumab) in Kombination mit zweimal wöchentlich CHOP versus zweimal wöchentlich CHOP allein und konsolidiert mit autologer Stammzelltransplantation bei jungen Patienten mit zuvor unbehandeltem systemischem peripherem T-Zell-Lymphom
Krankenhaus Nordwest GmbH
Klinik für Onkologie und Hämatologie
DEUTSCHLAND
Hessen
MARBURG
SONNET: Phase II, multizentrische offene Studie zur Beurteilung der Wirksamkeit einer Kombination von Lanreotide Autogel 120mg und Temozolomid bei Patienten mit progressivem endokrinen enteropankreatischen Tumor - Eine Pilotstudie
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
Klinik für Visceral- Thorax- und Gefäßchirurgie
FRANKREICH
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - FR
CHU de Lyon HCL - GH Sud
Service d'hématologie clinique
ITALIEN
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
ITALIEN
LOMBARDIA
MILANO
A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial
Fondazione IRCCS Istituto Nazionale dei Tumori
S.S. Oncologia Medica Gastroenterologica
KANADA
Québec
MONTRÉAL
RADIANT 4: A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - CA
Hôpital Royal Victoria - Royal Victoria Hospital
Clinical Research Program
OSTERREICH
SALZBURG
SALZBURG
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
OSTERREICH
TIROL
INNSBRUCK
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
OSTERREICH
WIEN
WIEN
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
RADIANT-4: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
PORTUGAL
NORTE
PORTO
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia do Porto, EPE / IPOFG - CRO Porto
Serviço de Onco-Hematologia
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Hospital de Santa Maria - Centro Hospitalar Universitário Lisboa Norte, EPE
Serviço de Hematologia e Transplantação de Medula
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia - Centro de Lisboa
Departamento de Hematologia
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
CheckMate 436: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Hematología Clínica
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors - ES
Institution: Information not provided - ES
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
AVAIL-T: A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Oxfordshire
OXFORD
RomiCar - Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
Churchill Hospital
Department of Haematology
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy- BE
Erasme Hospital - ULB
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIEN
VLAAMS BRABANT
LEUVEN
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
DEUTSCHLAND
Baden-Württemberg
MANNHEIM
INVICTUS: Eine Phase-3-Studie zur Beurteilung der Sicherheit und Wirksamkeit von DCC-2618 bei Patienten mit fortgeschrittenem gastrointestinalen Stromatumor, die mit früheren Krebstherapien behandelt wurden.
Universitätsmedizin Mannheim
Sarkom-Zentrum
DEUTSCHLAND
Brandenburg
BAD SAAROW
INVICTUS: Eine Phase-3-Studie zur Beurteilung der Sicherheit und Wirksamkeit von DCC-2618 bei Patienten mit fortgeschrittenem gastrointestinalen Stromatumor, die mit früheren Krebstherapien behandelt wurden.
HELIOS Klinikum Bad Saarow
Sarkomzentrum Berlin-Brandenburg
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
POETIG: Phase 2-Studie mit Ponatinib bei Patienten mit metastatischem und / oder inoperablem gastrointestinalen Stroma-Tumor (GIST) nach Versagen oder Intoleranz einer früheren Therapie mit Imatinib
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Innere Medizin (Tumorforschung)
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
INVICTUS: Eine Phase-3-Studie zur Beurteilung der Sicherheit und Wirksamkeit von DCC-2618 bei Patienten mit fortgeschrittenem gastrointestinalen Stromatumor, die mit früheren Krebstherapien behandelt wurden.
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Innere Medizin (Tumorforschung)
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
GRID: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
ImadGist : A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
CLCC Léon Bérard
Cancérologie médicale - Sarcomes et GIST, Tumeurs rares
FRANKREICH
HAUTS-DE-FRANCE
LILLE
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmen - FR
CLCC Oscar Lambret
Département de cancérologie générale
FRANKREICH
HAUTS-DE-FRANCE
LILLE
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment - BE
CLCC Oscar Lambret
Département de cancérologie générale
FRANKREICH
ILE-DE-FRANCE
PARIS
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy - FR
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
Service d'oncologie médicale
FRANKREICH
ILE-DE-FRANCE
VILLEJUIF
Phase II Study of Oral AB1010 (Masitinib) in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
CLCC Institut Gustave Roussy
Département de Médecine oncologique - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
CYCLIGIST: Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
ALT GIST: A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) - FR
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
PESSAC
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - FR
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
ITALIEN
PUGLIA
SAN GIOVANNI ROTONDO
Randomized study in open at active control of IIIb phase, of Sunitinib vs Imatinib in the treatment of patients with metastasized gastrointestinal tumor whose disease is evolved under treatment of Imatinib
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
GRID: A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
VOYAGER: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene (Phase III) - CH
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - CH
Institution: Information not provided - CH
SPANIEN
Cataluña
BADALONA
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
SPANIEN
Cataluña
BARCELONA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Cataluña
BARCELONA
SeliGIST: A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Intrigue: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
POD1UM-303/InterAACT 2: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy - ES
Institution: Information not provided - ES
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. -GB
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
CAMN107A2409: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - UK
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
CAMN107A2409: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - UK
Royal Marsden Hospital
Section of Medicine
VEREINIGTES KONIGREICH
Greater London
SURREY
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy -GB
The Royal Marsden
Royal Marsden NHS Foundation Trust
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Institution: Information not provided - UK
FRANKREICH
BOURGOGNE-FRANCHE-COMTE
DIJON
BALLAD : Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma - FR
CHU Dijon Bourgogne - Hôpital François Mitterrand
Service d'hépato-gastroentérologie
VEREINIGTES KONIGREICH
Glasgow
GLASGOW
A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma - GB
Beatson West of Scotland Cancer Centre
VEREINIGTES KONIGREICH
Greater London
LONDON
A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours - UK
St Bartholomew's Hospital, Barts and The London NHS Trust
Centre for Endocrinology
Multinationale klinische Studie(n)
VEREINIGTE STAATEN
California
LOS ANGELES
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
VEREINIGTE STAATEN
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
Institution: Information not provided - BE
FRANKREICH
ILE-DE-FRANCE
PARIS
SCHWEIZ
Suisse Alémanique
BASEL
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) (coordination)
Novartis International AG
SPANIEN
Madrid
MADRID
Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST - REGISTRI
GEIS - Grupo Español de Investigación de Sarcomas
VEREINIGTE STAATEN
Delaware
WILMINGTON
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Incyte Corporation
VEREINIGTE STAATEN
Kansas
LAWRENCE
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC.
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
NAVIGATOR: A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
VEREINIGTE STAATEN
Texas
DALLAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene.
Arog Pharmaceuticals, Inc.
FRANKREICH
AUVERGNE-RHONE-ALPES
SAINT-GENIS-POUILLY